Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Purchased by Decheng Capital LLC

Decheng Capital LLC increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 7.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 76,772 shares of the company’s stock after buying an additional 5,000 shares during the period. Krystal Biotech comprises approximately 2.6% of Decheng Capital LLC’s holdings, making the stock its 7th biggest position. Decheng Capital LLC owned 0.27% of Krystal Biotech worth $12,027,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of KRYS. Wilmington Savings Fund Society FSB acquired a new stake in shares of Krystal Biotech during the 3rd quarter worth approximately $40,000. Covestor Ltd lifted its stake in Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after buying an additional 642 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Krystal Biotech during the fourth quarter worth about $119,000. KBC Group NV increased its holdings in shares of Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock worth $147,000 after acquiring an additional 297 shares during the period. Finally, Blue Trust Inc. boosted its stake in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock valued at $159,000 after purchasing an additional 433 shares during the period. Institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 13.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on KRYS shares. HC Wainwright reiterated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective for the company. Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Citigroup boosted their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and an average target price of $220.00.

Krystal Biotech Price Performance

KRYS stock opened at $168.06 on Friday. The company’s 50 day simple moving average is $176.37 and its 200-day simple moving average is $171.57. The firm has a market capitalization of $4.86 billion, a P/E ratio of 56.21 and a beta of 0.75. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same period in the previous year, the company posted $0.30 EPS. Krystal Biotech’s revenue was up 116.4% on a year-over-year basis. Sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).